MYC and lip and oral cavity carcinoma: Methotrexate is a preferred chemotherapeutic agent in oral cancer treatment and if the aforementioned scenario also applies for OSCC, appropriate clinical strategies need to be designed based on the presence/absence of the c-Myc oncoprotein in oral cancer.